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Objectives: Limited information is available on physician-related factors influencing 
therapeutic inertia (TI) in multiple sclerosis (MS). Our aim was to evaluate whether phy-
sicians’ risk preferences are associated with TI in MS care, by applying concepts from 
behavioral economics.
Design: In this cross-sectional study, participants answered questions regarding the 
management of 20 MS case scenarios, completed 3 surveys, and 4 experimental para-
digms based on behavioral economics. Surveys and experiments included standardized 
measures of aversion ambiguity in financial and health domains, physicians’ reactions to 
uncertainty in patient care, and questions related to risk preferences in different domains. 
The primary outcome was TI when physicians faced a need for escalating therapy based 
on clinical (new relapse) and magnetic resonance imaging activity while patients were on 
a disease-modifying agent.
results: Of 161 neurologists who were invited to participate in the project, 136 coop-
erated with the study (cooperation rate 84.5%) and 96 completed the survey (response 
rate: 60%). TI was present in 68.8% of participants. Similar results were observed for 
definitions of TI based on modified Rio or clinical progression. Aversion to ambiguity 
was associated with higher prevalence of TI (86.4% with high aversion to ambiguity vs. 
63.5% with lower or no aversion to ambiguity; p = 0.042). In multivariate analyses, high 
aversion to ambiguity was the strongest predictor of TI (OR 7.39; 95%CI 1.40–38.9), 
followed by low tolerance to uncertainty (OR 3.47; 95%CI 1.18–10.2).
conclusion: TI is a common phenomenon affecting nearly 7 out of 10 physicians caring 
for MS patients. Higher prevalence of TI was associated with physician’s strong aversion 
to ambiguity and low tolerance of uncertainty.
Keywords: multiple sclerosis, disease-modifying therapy, neuroeconomics, decision-making, risk aversion
2Saposnik et al. Decision-making in MS (DIScUTIR MS)
Frontiers in Neurology | www.frontiersin.org March 2017 | Volume 8 | Article 65
inTrODUcTiOn
Making decisions in medical care is a complex task (1). Physicians 
have limited education in both risk management and decision-
making at medical schools (2). Decisions based on erroneous 
assessments may result in incorrect patient and family expecta-
tions, and potentially suboptimal advice, treatment, and outcome.
In behavioral economics, uncertainty is a generic term that 
comprises risk and ambiguity. Risk applies to events with known 
probability (3). In contrast, ambiguity is a term reserved for 
events for which probabilities are unknown (3). Typically, people 
are averse to both ambiguity and risk, and the two aversions are 
independent of each other (4). Uncertainty is one of the most 
important contributing factors affecting decisions in medical 
care (5, 6). However, limited information is available regarding 
the role of aversion to ambiguity in medical decisions.
Appropriate multiple sclerosis (MS) care involves complex 
medical decisions as it requires consideration of multiple short- 
and long-term factors (e.g., imaging results, disease progression, 
patient’s characteristics, and their preferences, etc.). No evidence 
of disease activity is emerging as a new standard for treatment 
response and may be associated with improved long-term disabil-
ity outcomes. A more proactive management strategy, including 
earlier use of high-efficacy DMTs and close monitoring of the 
clinical and radiological response to treatment, is recommended 
to slow the progression of physical and cognitive impairments 
in patients with relapsing-remitting multiple sclerosis (RRMS) 
(7–9). Treatment escalation has been shown to reduce relapse 
rates, disability progression, and magnetic resonance imaging 
(MRI) activity (10).
Therapeutic inertia (TI) is a term introduced in 2006 to define 
the absence of treatment initiation or intensification in patients 
when treatment goals are unmet (11–14). In the context of MS, 
TI is defined as the lack of treatment initiation or escalation when 
there is evidence of disease activity (based on the clinical course 
and neuroimaging markers) (15, 16). It is possible that aversion 
to ambiguity contributes to TI as the probabilities of benefits with 
treatment escalation are typically less well known than with treat-
ment continuation. To address this possibility, we need a better 
understanding of physician-related factors influencing decisions 
about DMTs and the prevalence of TI in MS care. The application 
of experiments from behavioral economics would facilitate the 
recognition of physicians’ therapeutic preferences and beliefs 
about DMTs for MS in the real world (17).
We hypothesized that physicians’ ambiguity aversion or low 
tolerance to uncertainty are associated with TI and clinical 
decisions in MS care. In the present study, we thus assessed the 
prevalence of TI (and associated contributing factors) in typi-
cal clinical decisions among physicians caring for MS patients 
across Spain.
MaTerials anD MeThODs
We conducted a web-based study using the Qualtrics platform 
(http://qualtrics.com). The study comprised 20 MS case-
vignettes, 3 standardized surveys, and 4 behavioral experiments 
among practicing neurologists from Spain from November 3, 
2015 to March 31, 2016 (see protocol published elsewhere) (15). 
In brief, participants answered three components in the following 
order: (i) demographic information, (ii) behavioral experiments/
surveys, and (iii) case scenarios. Responses from case scenarios 
were analyzed in light of responses from the behavioral compo-
nent. MS case scenarios were derived from the most common 
situations in clinical practice as identified by experts in the field 
(Drs. Daniel Selchen and Angel P. Sempere). Behavioral experi-
ments were designed to assess risk and ambiguity aversion in the 
health and financial domains (exposure) (Figure 1) (15, 18, 19). 
Ambiguity aversion is defined as dislike for events with unknown 
probability over events with known probability (18). For example, 
an ambiguity-averse individual would rather choose a treatment 
where the probability of benefits or side effects are known (even 
if these are somewhat unfavorable) over one where these prob-
abilities are unknown. Specifically, participants were asked to 
choose between a visual option with known 50/50 probability of 
winning €400 or €0 and an option with unknown probability of 
the same outcomes. Gray bars represented the degree to which 
the winning probability was unknown (Figure  1). The degree 
of ambiguity aversion was defined as the proportion of times 
participants chose the 50/50 option over the ambiguous option. 
As the overall level of ambiguity aversion was pronounced in our 
sample (mean 61.7% preference for 50/50 option, i.e., the option 
with known probabilities) and to avoid using an arbitrary crite-
rion, we classified participants as highly ambiguity averse if they 
chose the 50/50 (known probability) option in each of the nine 
scenarios (Figure  1) (20). In order to evaluate the consistency 
of the relationship with the primary outcome, we also analyzed 
another definition of ambiguity aversion (choice of the known 
probability option instead of the option with the 50% unknown 
probability in scenario 5; Figure 1).
In principle, risk aversion is another factor that may influence 
clinical decisions (21). Risk aversion is defined as the tendency to 
prefer safe payoffs over probabilistic payoffs when the expected 
value of both options is identical (4, 18). A risk-averse patient 
would thus prefer a treatment that provides a small improve-
ment with certainty over a treatment that provides a larger or 
no improvement with equal chance (50/50). We evaluated risk 
aversion by identifying the safe amount for which a participant 
was indifferent between the safe and the risky option (22). This 
indifference amount, called certainty equivalent, reflects the 
value associated to the risky option and facilitates comparison 
between participants. For example, participants were asked what 
would be the minimal certain payoff that they would prefer over 
the equiprobable gamble of winning €400 or €0 (expected value of 
€200). The degree of risk aversion of each individual corresponded 
to the difference of the expected value of the risky option (€200) 
minus the participant’s response (proxy of certainty equivalent). 
A similar visual design and methodology was used to elicit 
aversion to risk and ambiguity in the health domains (questions 
#15 and #17) (15). Participants were asked to choose between 
Treatment A (50% probability of survival) and “Treatment B” (the 
probability of survival is unknown) with the gray bars quantify-
ing how much is unknown about the probability of survival.
We also used two standardized surveys to assess physicians’ 
willingness to take risks and tolerance to uncertainty. The German 
FigUre 1 |  Decision scenarios used to measure ambiguity in financial (a) and health (B) domains. Participants were told to imagine two different types or 
urns. For urn type A, they knew that 50% of the balls were red and the other 50% were blue. For urn type B, they did not know the exact proportion of blue to red 
balls, with the gray bar representing the unknown proportion of balls. For the financial domain, participants knew that if they drew a blue ball, they would win the full 
amount of $400. If they drew a red ball, they would win $0. For the health domain, participants decided between two treatments for a patient. With “Treatment A,” 
the patient had a 50% probability of survival. With “Treatment B,” the exact probability of survival was unknown, with the gray bar representing the unknown 
probability.
3
Saposnik et al. Decision-making in MS (DIScUTIR MS)
Frontiers in Neurology | www.frontiersin.org March 2017 | Volume 8 | Article 65
Socio-Economic Panel (SOEP) is a validated survey that evaluates 
willingness to take risks in different domains (financial matters, 
own health, driving, own occupation, etc.) (23). We used ques-
tions of the form: “How would you rate your willingness to take 
risks in the following areas….”? Areas included financial matters, 
driving, occupation, etc., and responses could range from 0 (not 
at all) to 10 (very much).
The second survey measured physicians’ tolerance to uncer-
tainty in patient care, using the reaction to uncertainty test (24). It 
comprises five questions to be rated from 0 to 5 that when added 
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gives a total score (25). Low tolerance to uncertainty was defined 
as values below the median of the total score. Further details of 
the protocol were published elsewhere (15).
Participants
Practicing neurologists actively involved in the care of 
patients with MS from across Spain were invited to participate 
in our study by the Spanish Society of Neurology (Sociedad 
Española d8e Neurologia-SEN). Physicians whose practice 
was primarily in caring for MS patients were classified as 
“MS specialists.” All participants received compensation for 
completing the survey.
Definitions
For the primary analysis, disease activity was defined as a clinical 
relapse plus the presence of new brain lesions in follow-up MRI 
scans with at least one gadolinium-enhancing lesion (26, 27). 
In a sensitivity analysis, we also used the European Medicines 
Agency (EMA) and the modified Rio criteria to evaluate varia-
tions in TI. For example, the EMA approves escalating therapy 
from interferon-beta to natalizumab or fingolimod in patients 
who had at least one relapse in the previous year and either ≥9 
T2 hyperintense lesions or ≥1 gadolinium-enhancing T1 lesion 
on brain MRI (26, 27). The high-risk profile according to the 
modified Rio score includes either an MRI with more than 5 
new T2 lesions (1 point) or 1 relapse in the first year (1 point) or 
two relapses within the first year of treatment (2 points) or the 
combination of these criteria (8, 28). The use of these definitions 
combining a clinical relapse and MRI activity is consistent with 
recent evidence regarding the risk of treatment failure among 
patients receiving interferon-beta (29).
Disease progression was defined as at least one point worsen-
ing from baseline in the Expanded Disability Status Scale (EDSS) 
score (Table S1 in Supplementary Material) (28).
Recent meta-analysis confirmed that alemtuzumab, natali-
zumab, and fingolimod are the best available choices for prevent-
ing clinical relapses in patients with RRMS (30). However, there 
is no consensus algorithm available despite the publication of 
national or regional recommendations (8, 16, 26, 31–33). As a 
result, the current landscape of DMTs for the treatment of RRMS 
includes first-line therapies (beta interferons, glatiramer acetate, 
teriflunomide, and dimethyl fumarate) and second-line therapies 
(fingolimod, natalizumab, and alemtuzumab). For the present 
analysis, we used the aforementioned scheme according to the 
current clinical practice.
Outcome Measures
The primary outcome of the study was the proportion of par-
ticipants who exhibited TI and its association with aversion to 
ambiguity (14, 18). TI (presence/absence) was determined as the 
lack of escalation of therapy given disease activity while patients 
received a DMT in at least one case scenario.
Secondary outcome measures included the association 
between tolerance to uncertainty, risk aversion, and the SOEP 
surveys, on the one hand, and with TI and therapeutic decisions, 
on the other hand.
statistical analysis
The primary analysis assessed the possible association between 
physicians’ aversion to ambiguity and TI. A multiple logistic 
regression analysis with backward selection was completed to 
determine the association between physicians’ characteristics 
with the primary outcome of interest. We included the following 
explanatory variables: age, gender, MS patients seen per week, 
practice setting (academic vs. non-academic), % of time devoted 
to clinical care, coauthor in a peer-reviewed publication within 
the last 3 years (yes/no), attendance to the European Committee 
for Treatment and Research in Multiple Sclerosis 2015 annual 
meeting, risk aversion, overconfidence, tolerance to uncertainty 
(above/below the median), willingness to take risks in all domains 
(SOEP survey—above/below the median), and herding (follow-
ing recommendations made by another colleague). As there was 
a high correlation between MS specialists (self-defined) and 
number of MS patients assessed per week (Spearman’s rho = 0.58; 
p < 0.001), only the latter was entered in the multivariate analysis. 
Linear regression analysis was used to test for a relation between 
the number of patients assessed per week and the outcomes of 
interest. A sensitivity analysis was completed by using different 
criteria of TI and building models including all variables of inter-
est (Supplementary Material).
All tests were 2-tailed, and p-values <0.05 were considered 
significant. We calculated the power of the study for the primary 
outcome of interest with an alpha error level of 0.05 and found 
that we had 100% power to detect a 27% difference between 
groups for the primary outcome measure.
The study was approved by the Research Ethics Board of St. 
Michael’s Hospital, University of Toronto, ON, Canada.
resUlTs
Out of the 161 neurologists who were invited to participate in 
the study from representative areas of Spain, 136 cooperated 
(cooperation rate 84.5%) and 96 completed the survey (response 
rate 60%). There was representation from all regional territories 
except the Canary Islands (Figure S1 in Supplementary Material).
Overall, the mean (SD) age was 39.5 (±8.5) years; 51 (53%) 
were female. Two-thirds primarily focused their practice on MS 
care (n = 64; 66.7%). The mean years in practice was 14, com-
monly assessing 20 (±15) MS patients per week. Table 1 sum-
marizes baseline characteristics of the study population.
For the measurement of risk preferences, the mean safe payoffs 
were €200 (±33) in the financial domain and 12.3 (±4.3) years in 
the health domain.
For the measurement of ambiguity, total aversion to unknown 
probability (all nine scenarios) was observed in 23% of partici-
pants in the financial domain and 27.1% for the health domain. 
For the scenario where the ambiguous option contained 50% 
unknown probability (scenario 5), 59.4% of participants chose 
the known probability (50/50) option in the financial domain and 
73.7% in the health domain. The median time for completing the 
study was 39 min (IQR 30–52 min).
Therapeutic inertia was present in 68.8% of participants. Similar 
findings were observed when we applied the modified Rio criteria 
(61.5%), modified Rio or neurological progression (67.7%), but 
TaBle 2 | Prevalence of therapeutic inertia (Ti) among multiple sclerosis 
(Ms) specialists and general neurologists.
Outcome Ms specialists 
N = 64 (66.7)
general 
neurologists 
N = 32 (33.3)
p-Value
Ti (criterion)
Clinico-radiological 40 (62.5) 26 (81.3) 0.062
European Medicines Agency 13 (20.3) 15 (46.9) 0.007
Modified Rio or progression 39 (60.9) 26 (81.3) 0.045
TaBle 1 | Baseline characteristics of participants.
characteristics
age (mean ± SD), in years 39.5 ± 8.5
sex no. of participants (%)
Male 45 (46.9)
Female 51 (53.1)
specialty
Multiple sclerosis (MS) specialist 64 (66.7)
General neurologist who care for MS patients 32 (33.3)
Practice setting
Academic 48 (50.0)
Community 26 (27.1)
Both (academic and community) 21 (21.9)
Other 1 (1.0)
% time in clinical practice
>75% 70 (72.9)
Years in practice, mean ± SD 14.1 ± 10
Ms patients seen per week, mean ± SD 20 ± 15
attended latest european committee 
for Treatment and research in Multiple 
sclerosis conference
56 (58)
author of a peer-reviewed publication in 
the last 3 years
79 (82.3)
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TI was less common (29.2%) when we applied the EMA criteria. 
TI was less common among MS specialists (Table 2). Moreover, a 
higher number of MS patients seen per week were associated with 
a significantly lower risk of TI. Linear regression analysis suggests 
that the assessment of 10 more MS patients per week (from a 
baseline of 16) was associated with lower risk of TI (adjusted 
coefficient −10.2; 95%CI −18.4 to −2.0).
aversion to ambiguity and Ti
For the primary outcome, high aversion to ambiguity in the finan-
cial domain was associated with TI (86.4 vs. 63.5%; p = 0.042). 
High ambiguity aversion in the health domain was not associated 
with TI (76.9 vs. 65.7%; adjusted OR 1.79, 95%CI 0.61–5.25). 
Multivariable logistic regression analysis showed that high aver-
sion to ambiguity in the financial domain was the strongest predic-
tor of TI, significantly stronger even than aversion to ambiguity in 
the health domain (adjusted OR 7.39; 1.40–38.9) (Table 3; Table 
S2 and Figures S2 and S3 in Supplementary Material). The results 
were also consistent when ambiguity aversion was defined by 50% 
unknown probability (adjusted OR 3.29; 1.21–8.99).
A sensitivity analysis showed that high aversion to ambiguity 
was also the strongest predictor of TI when applying the EMA 
criteria (adjusted OR 8.01; 95%CI 1.73–37.1) for the composite 
outcome of disease activity (modified Rio criteria) or evidence of 
progression (OR 4.41; 95%CI 1.04–18.7). The results remained 
consistent when models included all explanatory variables of 
interest, including number of patients seen per week (Table S2 in 
Supplementary Material).
Low tolerance to uncertainty (physician’s reaction to uncer-
tainty survey) was associated with higher prevalence of TI (85.4 vs. 
56.4%; adjusted OR 4.73, 1.63–13.7) (Figure 2). The association 
between TI and low tolerance to uncertainty was independent of 
the association between TI and high ambiguity aversion (Table S2 
in Supplementary Material).
Conversely, willingness to take risk in multiple domains (as 
measured by the SOEP survey) or herding was not associated 
with TI (Table S2 in Supplementary Material).
DiscUssiOn
Multiple sclerosis patients and their treating physicians are rou-
tinely confronted with uncertainties concerning the diagnosis, 
prognosis, disease course, and disease-modifying therapies (27).
In the present study, we applied validated experiments and 
surveys from behavioral economics to evaluate the association 
between physicians’ aversion to risk or ambiguity and TI (15). 
We found that TI affects nearly 7 out of 10 neurologists caring 
for MS patients but was less common among physicians with 
greater patient volumes per week or MS specialists. High aversion 
to ambiguity was the strongest predictor of TI even after adjust-
ing for relevant confounders (e.g., age, practice setting, years in 
practice, percentage of time in clinical practice, overconfidence, 
time of survey completion, etc.). Lower tolerance to uncertainty 
was also associated with 3.5-fold higher risk of TI. On average, 
the assessment of 10 more MS patients per week was associated 
with lower risk of TI. Our results were consistent when employing 
various criteria on when to escalate therapy, as defined based on 
disease activity and/or progression. Physicians’ characteristics 
(e.g., age, gender, practice setting, years in practice, percentage of 
time in clinical practice) were not associated with TI.
In the last few years, there has been an increase in the avail-
ability and variability of therapeutic options for the management 
of MS. Although having more options is perceived as beneficial, 
consumer studies in psychology suggest the higher the number of 
options, the more difficult the decision, leading to a higher number 
of less satisfactory choices (labeled as “choice overload”) (34, 35).
Our results have practical implications that deserve comment. 
We showed that either a simple experiment or a short survey out-
side of the medical domain that assess aversion to ambiguity or 
tolerance to uncertainty may help to identify TI among neurolo-
gists and MS experts. The lack of escalation of therapies may lead 
to greater disability of MS patients, increasing the health-care 
costs and production losses due to incapacity to work. In Europe, 
the mean annual cost per person with MS has been estimated 
at €23,000 for EDSS score 0.0–3.5, rising as disability increases 
to €46,000 for EDSS score 4.0–6.5, and €77,000 for EDSS score 
7.0–9.5 (36).
FigUre 2 | Prevalence of therapeutic inertia (Ti) among participants with high ambiguity aversion in the financial domain and low tolerance to 
uncertainty in patient care. See description in the text for the criteria of TI. *p = 0.042; **p < 0.01.
TaBle 3 | effect of high ambiguity aversion according to different definitions of therapeutic inertia (Ti).
Outcome Prevalence (%) of Ti in the 
cohort
adjusted model for ambiguity 
aversiona
adjusted model for 
ambiguity aversionb
Or (95%ci) c-statistics Or (95%ci) c-statistics
Ti (criterion)
Clinico-radiological 66 (68.8) 7.39 (1.40–38.9) 0.804 8.01 (1.01–73.3) 0.828
European Medicines Agency 28 (29.2) 8.02 (1.37–37.1) 0.777 7.17 (1.36–37.6) 0.796
Modified Rio or progression (Expanded Disability Status Scale >1) 65 (67.7) 4.41 (1.04–18.7) 0.791 4.01 (0.83–19.3) 0.811
aModels derived from stepwise logistic regression with backward selection with p > 0.2 level for removal.
bModels derived from logistic regression including all variables of interest (age, sex, number of multiple sclerosis patients seen per week, practice setting, academic profile, risk 
aversion, ambiguity aversion, tolerance to uncertainty, herding, and overconfidence).
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Factors associated with TI include low volume of MS patients, 
non-specialty, and physicians’ ambiguity preferences (e.g., low 
tolerance to uncertainty in patient care, high aversion to financial 
ambiguity). Taken together, TI may be explained, at least in part, 
by (i) the aversion of neurologists to escalate treatment when 
the available options can have more serious side effects; (ii) the 
limited education (or experience) of neurologists regarding the 
risk profile of new DMTs, and (iii) participants’ preference to 
continue with a known medication profile vs. the unknown risks 
of a new agent. Other studies have found that TI was associated 
with lack of training and clinical uncertainty (5). Physicians with 
better coping strategies and more tolerance to ambiguity may 
be more likely to choose optimal treatments leading to better 
patients’ outcomes (37).
The prevailing significance of aversion to ambiguity in the 
financial over the health domain in the multivariate analysis may 
be related to either methodological differences when measuring 
each variable or suggest an underlying hardwired representa-
tion of aversion to ambiguity and TI that is easier elicited in the 
financial domain (18).
The results of DIScUTIR MS may not only be relevant for 
MS care but also be seen as the initial step to inform the design 
of a larger worldwide intervention, including physicians’ high 
aversion to ambiguity in the financial domain and low tolerance 
to uncertainty in patient care when assessing the use of new 
agents.
Our study has limitations that deserve comment. First, the 
study was conducted in Spain exclusively, thus limiting the gen-
eralizability of our results to other cultural contexts. Moreover, 
some participants may have responded based on their current 
local restrictions to prescribe specific DMTs. However, cognitive 
distortions and risk preferences have been identified in several 
studies of physicians’ decisions across the world and are thus 
probably not limited to a specific region or country (38). Second, 
the assessment of case scenarios may not fully capture decisions 
made in real clinical practice, even though specialists designed 
and recognized the scenarios as close to daily practice. In addi-
tion, participants may refer their MS patients to an MS outpatient 
clinic as part of a standard practice, which may have influenced 
our results. Third, considering the relatively low sample size, our 
findings should be viewed as exploratory. However, our results 
were consistent across several criteria of TI and adjusted models. 
Fourth, the concept and definition of TI applied to MS care is 
not widely disseminated and not yet generally accepted in MS 
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care. Nevertheless, we used a practical definition of TI (absence of 
escalation in the face of a clinical relapse plus evidence of imaging 
activity), which is supported by consensus panels, as well as by 
MS studies and other areas showing improvements in clinical 
outcomes when escalating therapies (i.e., blood pressure and 
diabetes) (14, 39, 40).
Despite these limitations, our study is the first step in the 
understanding of how specific characteristics of physicians 
(i.e., high ambiguity aversion, low tolerance to uncertainty) 
directly influence therapeutic decisions in MS patients beyond 
demographic factors, medical expertise, practice setting, patients’ 
factors, or their treatment preferences. Using a novel approach 
that combines case-vignettes with the assessment of cognitive 
distortions through experiments from behavioral economics, 
we were able to expand our current understanding of decision-
making under uncertainty in MS care.
Although MS experts have an expanded therapeutic arse-
nal compared to a decade ago, our study shows that nearly 
7 out of 10 neurologists exhibited TI leading to suboptimal 
decisions. The results of DIScUTIR MS provide vital infor-
mation to initiate discussions on behavioral strategies and 
incentives in order to ameliorate physicians’ inertia to escalate 
therapies leading to better outcomes and quality of life for 
MS patients (41). For example, training in risk management 
and decision-making, as well as, educational interventions are 
needed to overcome knowledge-to-action gaps (and reduce 
the TI) in MS care. This is relevant considering the lack of 
well-established MS guidelines concerning clinical scenarios 
under uncertainty or progression of disease and the limited 
understanding on how physicians’ preferences (e.g., aversion 
to ambiguity) have a global impact on medical and daily life 
decisions (42).
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